MATWIN (Maturation & Accelerating Translation With Industry) is the only French open-innovation platform specifically dedicated to oncology. MATWIN, a wholly owned subsidiary of Unicancer group (gathering all the French Comprehensive Cancer Centres) offers several actions (expertise, accelerating program, events, etc.) aiming at accelerating the development of innovative projects dedicated to the fight against cancer. It mobilizes a network of international experts, from both academia and industry severally committed to shortening the time it takes to transfer innovations to patients. MATWIN has already supported more than 260 projects and has fostered the creation of more than 45 startups. For more than 14 years now the whole French ecosystem (major groups, biotechs, canceropoles, TTOs, competitive clusters, incubators, investors, etc.) is involved within MATWIN’s initiative confirming therefore the benefit and added value of this open innovation national action focused on a public health issue.
Among other actions ...
MATWIN offers to project leaders (academic or start-up) an accelerating program in 3 steps:
Double international assessment
Coaching to optimize projects structuring and industrial development potential
Access to MATWIN’s partners’ network (major groups, biotech, investors) to accelerate projects’ development.
To do so, MATWIN’s process relies on a partnership with major international groups involved in oncology (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, MSD, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) that are concerned with sourcing and supporting projects with high industrial development potential.